Get the Stockscreener App
8.105
0.19%
0.015
After Hours:
7.95
-0.155
-1.91%
Wave Life Sciences Ltd stock is traded at $8.105, with a volume of 2.01M.
It is up +0.19% in the last 24 hours and up +5.26% over the past month.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
See More
Previous Close:
$8.09
Open:
$8.04
24h Volume:
2.01M
Relative Volume:
1.49
Market Cap:
$1.29B
Revenue:
$53.61M
Net Income/Loss:
$-142.52M
P/E Ratio:
-7.3018
EPS:
-1.11
Net Cash Flow:
$-141.83M
1W Performance:
-7.37%
1M Performance:
+5.26%
6M Performance:
-22.14%
1Y Performance:
+49.82%
1-Day Range:
$7.80
$8.11
1-Week Range:
$7.80
$8.97
52-Week Range:
$5.04
$16.73
Wave Life Sciences Ltd Stock (WVE) Company Profile
Name
Wave Life Sciences Ltd
Sector
Industry
Phone
617-949-2900
Address
7 STRAITS VIEW, SINGAPORE
Compare WVE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WVE
Wave Life Sciences Ltd
|
8.105 | 1.29B | 53.61M | -142.52M | -141.83M | -1.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
374.46 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
435.00 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.94 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
638.90 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
289.75 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-04-25 | Initiated | Canaccord Genuity | Buy |
| Jul-28-25 | Initiated | Oppenheimer | Outperform |
| Jul-16-25 | Initiated | Citigroup | Buy |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-25 | Initiated | Wedbush | Outperform |
| Feb-25-25 | Initiated | Jefferies | Buy |
| Oct-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-27-24 | Resumed | JP Morgan | Overweight |
| Sep-19-24 | Initiated | B. Riley Securities | Buy |
| Sep-09-24 | Initiated | JP Morgan | Overweight |
| May-15-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Raymond James | Outperform |
| May-24-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-31-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Jul-15-19 | Initiated | Cowen | Market Perform |
| Apr-17-19 | Reiterated | H.C. Wainwright | Buy |
| Aug-07-18 | Initiated | Stifel | Buy |
| Jul-23-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Feb-15-17 | Initiated | H.C. Wainwright | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | JMP Securities | Mkt Outperform |
| Dec-07-15 | Initiated | Jefferies | Buy |
| Dec-07-15 | Initiated | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Wave Life Sciences Ltd Stock (WVE) Latest News
Wave Life Sciences Shareholders Approve Key Proposals - TipRanks
Is Wave Life Sciences Ltd. the Top Chart Pick This WeekAI Based High Gain Watchlist Scanner Shared - beatles.ru
Wave Life Sciences Director Sells 1,127 Shares for $8.75 Each. - AInvest
Oppenheimer Initiates Wave Life Sciences(WVE.US) With Buy Rating, Announces Target Price $24 - 富途牛牛
CCORF Initiates Wave Life Sciences(WVE.US) With Buy Rating, Announces Target Price $19 - 富途牛牛
Wave Life Sciences Highlights RNA Platform Advancements - TipRanks
A Quick Look at Today's Ratings for Wave Life Sciences(WVE.US), With a Forecast Between $18 to $24 - 富途牛牛
Wave Life Sciences stock a new Buy at Canaccord Genuity (WVE) - Seeking Alpha
Wave Life Sciences stock initiated with Buy rating by Canaccord - Investing.com Australia
This AeroVironment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Wave Life Sciences Ltd. shares rise 6.03% premarket after OraSure Technologies appoints new Chief Commercial Officer. - AInvest
Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Trimmed Their Revenue Forecasts By 13% - simplywall.st
Wave Life Sciences signals key Q3 and Q4 data catalysts as INHBE and AATD programs advance - MSN
When is Wave Life Sciences Ltd. stock expected to show significant growthSuperior stock growth - Jammu Links News
What analysts say about Wave Life Sciences Ltd. stockConsistent triple-digit returns - Jammu Links News
Earnings Update: Wave Life Sciences Ltd. (NASDAQ:WVE) Just Reported And Analysts Are Trimming Their Forecasts - 富途牛牛
How many analysts rate Wave Life Sciences Ltd. as a “Buy”Triple-digit wealth increases - Jammu Links News
What are analysts’ price targets for Wave Life Sciences Ltd. in the next 12 monthsUnlock powerful trading strategies for gains - Jammu Links News
What is Wave Life Sciences Ltd. company’s growth strategyDiscover undervalued stocks ready to soar - Jammu Links News
Is Wave Life Sciences Ltd. a growth stock or a value stockExceptional profit potential - Jammu Links News
What are the latest earnings results for Wave Life Sciences Ltd.Capitalize on emerging market sectors - Jammu Links News
How does Wave Life Sciences Ltd. compare to its industry peersBuild a portfolio that withstands market volatility - Jammu Links News
Insights Into WAVE Life Sciences's Upcoming Earnings - 富途牛牛
How strong is Wave Life Sciences Ltd. company’s balance sheetSmart Portfolio Outlook For Consistent Profits - Jammu Links News
Why is Wave Life Sciences Ltd. stock attracting strong analyst attentionPost Market Updates For Consistent Profits - Jammu Links News
Wave Life Sciences Ltd. shares rise 2.72% intraday after TELUS CORPORATION's ESG initiatives and new product focus. - AInvest
WAVE Life Sciences Reports Q2 2025 Earnings: RNA Editing Progress Amid Revenue Decline and Strong Cash Position - AInvest
Wave Life Sciences Second Quarter 2025 Earnings: Misses Expectations - simplywall.st
Wave Life Sciences Ltd. (NASDAQ:WVE) Q2 2025 Earnings Call Transcript - Insider Monkey
Need To Know: The Consensus Just Cut Its Wave Life Sciences Ltd. (NASDAQ:WVE) Estimates For 2025 - Yahoo Finance
Wave Life Sciences Earnings Call: Clinical Advances Amid Financial Challenges - TipRanks
Is it the right time to buy Wave Life Sciences Ltd. stockStock Strategy Recommendation From AI Tools - jammulinksnews.com
Wave (WVE) Q2 Revenue Drops 56% - AOL.com
Wave Life Sciences Ltd.'s (NASDAQ:WVE) 26% Share Price Surge Not Quite Adding Up - simplywall.st
What catalysts could drive Wave Life Sciences Ltd. stock higher in 2025Expert Picks Tips For Beginners - Jammu Links News
Wave Life Sciences: Q2 Earnings Snapshot - Huron Daily Tribune
Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates - sharewise.com
WAVE Life Sciences Ltd (WVE) Q2 2025 Earnings Call Highlights: Progress in RNA Editing Amid ... - Yahoo Finance
Wave (WVE) Q2 Revenue Drops 56% - The Motley Fool
Wave Life Sciences Advances RNA Medicine Pipeline - TipRanks
WAVE Life Sciences Q2 2025 Earnings Call Transcript - MarketBeat
Wave Life Sciences 2025 Q2 Earnings Revenue Drops 56%, Net Loss Widens - AInvest
Top Risks to Consider Before Buying Wave Life Sciences Ltd. StockOversold Recovery Opportunity Stocks Attract Buyers - metal.it
WaveLife Flat on Q2 Results - Baystreet.ca
WAVE Life Sciences Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Wave Life Sciences Ltd earnings missed by $0.04, revenue fell short of estimates - Investing.com Nigeria
Wave Life Sciences Ltd Stock (WVE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.02%
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):